Extended In-Use Stability of Intravenous Actemra

This letter responds to your request for information on extended in-use stability of Actemra® (tocilizumab) diluted for intravenous (IV) infusion.

Download article Download

Last updated August 10, 2023

Summary

  • Roche has performed an additional in-use stability study that confirms physical and chemical stability of Actemra concentrate for solution for IV infusion under specific conditions:
    • diluted with 0.9% NaCl to 0.1 mg/mL and 8.0 mg/mL
      • in PE, PVC or PP IV bags, and
        • for 24 hours at 30°C followed by up to 14 days at 2-8°C.
        • Roche refers the user to the approved label for product use, including Storage and Stability information.

          Abbreviations

          NaCl=sodium chloride

          PE=polyethylene

          PP=polypropylene

          PVC=polyvinyl chloride

          Prescribing information

          The fully diluted ACTEMRA solutions for infusion using 0.9% Sodium Chloride Injection, USP may be stored at 2° to 8°C (36° to 46°F) or room temperature for up to 24 hours and should be protected from light.

          The fully diluted ACTEMRA solutions for infusion using 0.45% Sodium Chloride Injection, USP may be stored at 2° to 8°C (36° to 46°F) for up to 24 hours or room temperature for up to 4 hours and should be protected from light.

          Extended in-use stability of Actemra IV

          Roche evaluated the stability and product quality of Actemra concentrate for solution for IV infusion diluted to 0.1 mg/mL and 8.0 mg/mL in PE, PVC or PP IV bags containing 0.9% NaCl.[1-3]

          Physical and chemical stability of Actemra IV was demonstrated for 24 hours at 30°C, followed by up to 14 days at 2-8°C.

          Study objectives 

          The study evaluated physical and chemical stability and did not cover any microbiological aspects.[1-3]

          All study samples were assessed by product quality attributes that could potentially be impacted by such study conditions. The analytical tests included analysis of[1-3]

          • the general aspects, including pH, particles, color, clarity, opalescence,
            • purity,
              • protein content and
                • potency.
                    

                  Study methodology

                  The in-use compatability study procedures are summarised below:[1-3]

                     
                  1. Two Actemra IV solutions were prepared by using Sodium Chloride 0.9% IV bags. The two concentrations tested were 0.1 mg/mL and 8.0 mg/mL, in PE, PVC and PP IV bags.
                    1. The IV solutions were held at 30 ºC for 24 hours under diffused light conditions, followed by storage at 2-8°C for 14 days (protected from light).
                      1. Simulated infusions were conducted after the described storage conditions using administration sets with standard infusion lines.

                        Disclaimer

                        Consult the approved label for product use, including Storage and Stability information. Any actions beyond the approved label information are the responsibility of the user. This assumes the product has been prepared under controlled and validated aseptic conditions.

                        References

                        1. Data on file (Accessed on July 12 2023).
                          1. Data on file (Accessed on July 12 2023).
                            1. Data on file (Accessed on July 12 2023).

                              Welcome to Medically

                              The Roche Science Hub

                              This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

                              Not a healthcare professional? Browse:

                              This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

                              You are Leaving Medically

                              By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

                              You are Leaving the Global Medically Site

                              By following this link, you are being redirected to another Roche page.